Restart Life Sciences Corp.
NMLSF
$0.05
-$0.02-33.07%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 82.14% | 7.71% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 81.79% | 7.78% | |||
| Operating Income | -81.79% | -7.78% | |||
| Income Before Tax | 26.37% | -4.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.37% | -4.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.37% | -4.15% | |||
| EBIT | -81.79% | -7.78% | |||
| EBITDA | -82.14% | -7.71% | |||
| EPS Basic | 32.56% | 2.27% | |||
| Normalized Basic EPS | -71.43% | 0.00% | |||
| EPS Diluted | 60.27% | -1.39% | |||
| Normalized Diluted EPS | -71.43% | 0.00% | |||
| Average Basic Shares Outstanding | 9.47% | 6.84% | |||
| Average Diluted Shares Outstanding | 9.47% | 6.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||